Conditions: Non-Small Cell Lung Cancer
Keywords: NSCLC Lung Cancer ATLAS Avastin Tarceva
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1145
Healthy volunteers: no

Brief summary:
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: bevacizumab intervention 2: placebo intervention 3: erlotinib HCl
Intervention descriptions: intervention 1: Intravenous repeating dose intervention 2: Oral repeating dose intervention 3: Oral repeating dose

Protocol document: